Editorial: Senate should retain essence of bill on "pay for delay" deals

The Senate should stand by a House bill that would curb "pay for delay" deals between brand-name and generic-drug companies in order to save consumers billions of dollars and reduce the federal budget deficit, according to this New York Times editorial. House lawmakers passed the bill last week with compromise language that would allow companies to overcome a presumption deeming such agreements illegal.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC